[EN] NEW THERAPEUTIC USES OF COMPOUNDS<br/>[FR] NOUVELLES UTILISATIONS THÉRAPEUTIQUES DE COMPOSÉS
申请人:PROXIMAGEN LLC
公开号:WO2021195406A1
公开(公告)日:2021-09-30
The present invention relates to the treatment and prevention of pulmonary inflammation using a compound of Formula (I) or a pharmaceutically acceptable salt, solvate, hydrate, N-oxide, and/or prodrug thereof. The pulmonary inflammation may be associated with acute lung injury (ALI) and/or acute respiratory distress syndrome (ARDS), which in turn may be associated with viral induced cytokine surge. Such diseases and conditions may be caused by a coronavirus, i.e., severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2), severe acute respiratory syndrome coronavirus (SARS-CoV), or Middle East respiratory syndrome coronavirus (MERS-CoV). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
本发明涉及使用化合物I式或其药用可接受的盐、溶剂化合物、水合物、N-氧化物和/或前药来治疗和预防肺部炎症。肺部炎症可能与急性肺损伤(ALI)和/或急性呼吸窘迫综合征(ARDS)相关联,而这些可能与病毒引起的细胞因子激增有关。这些疾病和状况可能由冠状病毒引起,即严重急性呼吸综合征冠状病毒2(SARS-CoV-2)、严重急性呼吸综合征冠状病毒(SARS-CoV)或中东呼吸综合征冠状病毒(MERS-CoV)引起。本摘要旨在作为特定领域搜索的扫描工具,不限制本发明。